Missed Opportunities for Screening and Management of Dysglycemia among Patients Presenting with Acute Myocardial Infarction in North India: The Prospective NORIN STEMI Registry

Dysglycemia is a major and increasingly prevalent cardiometabolic risk factor worldwide, but is often undiagnosed even in high-risk patients. We evaluated the impact of protocolized screening for dysglycemia on the prevalence of prediabetes and diabetes among patients presenting with ST-segment elev...

Full description

Saved in:
Bibliographic Details
Published in:Global heart 2022-08, Vol.17 (1), p.54
Main Authors: Ostrominski, John W, Vaduganathan, Muthiah, Girish, Meennahalli Palleda, Gupta, Puneet, Hendrickson, Michael J, Qamar, Arman, Arora, Sameer, Pandey, Ambarish, Bansal, Ankit, Batra, Vishal, Mahajan, Bhawna, Mukhopadhyay, Saibal, Yusuf, Jamal, Tyagi, Sanjay, Bhatt, Deepak L, Gupta, Mohit D
Format: Article
Language:English
Subjects:
cardiometabolic
diabetes
Diabetes Mellitus - diagnosis
Diabetes Mellitus - epidemiology
Glycated Hemoglobin - analysis
Humans
low- and middle-income countries
Middle Aged
Myocardial Infarction
Original Research
Prediabetic State - diagnosis
Prediabetic State - epidemiology
Prediabetic State - therapy
prevention
Prospective Studies
Registries
Risk Factors
screening
ST Elevation Myocardial Infarction - diagnosis
ST Elevation Myocardial Infarction - epidemiology
ST Elevation Myocardial Infarction - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dysglycemia is a major and increasingly prevalent cardiometabolic risk factor worldwide, but is often undiagnosed even in high-risk patients. We evaluated the impact of protocolized screening for dysglycemia on the prevalence of prediabetes and diabetes among patients presenting with ST-segment elevation myocardial infarction (STEMI) in North India. We conducted a prospective NORIN STEMI registry-based study of patients presenting with STEMI to two government-funded tertiary care medical centers in New Delhi, India, from January to November 2019. Hemoglobin A1c (HbA1c) was collected at presentation as part of the study protocol, irrespective of baseline glycemic status. Among 3,523 participants (median age 55 years), 855 (24%) had known diabetes. In this group, baseline treatment with statins, sodium-glucose cotransporter 2 inhibitors, or glucagon-like peptide-1 receptor agonists was observed in 14%,
ISSN:2211-8160
2211-8179
2211-8179
DOI:10.5334/GH.1140